权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Steroid resistance of airway ILC2s

气道 ILC2 的类固醇抵抗

基本信息

批准号：
9914206
负责人：
Rafeul Alam
金额：
$ 45.4万
依托单位：
NATIONAL JEWISH HEALTH
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-05-15 至 2023-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9914206
关键词：
Abbreviations Acute Address Affect Airway Resistance Allergens Animal Model Antibodies Asthma Autoimmune Process B-Cell Lymphomas BMI1 gene Biological Blood Bronchoalveolar Lavage Cell Nucleus Cells Chronic Clinical Clinical Trials Complex Cytosol Development Dexamethasone Disease Epithelial Epithelium Exposure to Flow Cytometry Frequencies Genes Genetic Transcription Genomic approach Glucocorticoid Receptor Glucocorticoids Growth Factor Homologous Gene Human IL5 gene IL7 gene Immune response Immunodeficient Mouse In Vitro Inflammatory Interleukin-13 Leukemic Lymphocyte Lung Lymphoid Cell MAP Kinase Gene MAPK3 gene MEKs Mediator of activation protein Medical Care Costs Modality Modeling Molecular Moloney Leukemia Virus Mus Paper Pathway interactions Patients Phosphotransferases Play Polycomb Public Health Reporting Repressor Proteins Resources Retinoids Rhinovirus Role STAT protein Signal Pathway Signal Transduction Signaling Molecule Societies Source Steroid Receptors Steroid Resistance Steroid-resistant asthma Steroids Subgroup T-Lymphocyte TSLP gene Testing Th2 Cells Therapeutic Therapeutic Agents Therapeutic Intervention Thyroid Hormone Receptor Tumorigenicity Up-Regulation Virus Diseases Western Blotting airway hyperresponsiveness asthma model asthmatic patient base cost cytokine experimental study fMet-Leu-Phe receptor functional genomics genetic corepressor high risk human disease humanized mouse in vivo inhibitor/antagonist member mouse model neoplastic novel novel therapeutics preclinical study preclinical trial public health relevance receptor recruit resistance gene

项目摘要

Abstract: The glucocorticoid-type steroids are the mainstay of asthma therapy. A subgroup of asthmatic patients develops steroid resistance, which becomes a major therapeutic challenge and imposes a high cost to the society. An understanding the mechanism of steroid resistance is important. Asthma is driven by the type 2 immune response. Type 2 innate lymphoid cells (ILC2s) are an important source of type 2 cytokines. Two epithelial cytokines—IL33 and TSLP promote the development and function of ILC2s. We have recently reported that airway ILC2s, as compared to blood ILC2s, from a subgroup of asthmatic patients are steroid resistant in a TSLP (thymic stromal lymphopoietin)-dependent manner. Blood ILC2s become steroid resistant when exposed to TSLP but not IL33. We have uncovered a mechanism for this dichotomous effect. Steroids upregulate (protagonize) the receptors for TSLP but not IL33. By upregulating the receptors steroids lower their activation threshold. Steroids still antagonize many inflammatory pathways in these cells but, surprisingly, protagonize the pathways that directly interfere with the formation of the glucocorticoid receptor repressor complex. Consequently, these pathways upregulate type 2 cytokines unabated in the presence of steroids, which results in steroid resistance. Based upon these findings we hypothesize that activation of steroid protagonized receptors induces steroid resistance through upregulation of select signaling pathways that disrupt the formation of the glucocorticoid receptor (GR) repressor complex. We propose 3 specific aims to test the foregoing hypothesis. Under specific aim 1 we will study the molecular mechanism of TSLP-induced steroid resistance of ILC2s. We will examine how a novel signaling pathway involving MEK2-CBX7-PRC1, identified in preliminary experiments, hinders the organization of the GR repressor complex. We will use human blood and lung ILC2s to maintain human disease relevance. Specific aim 2 is devoted to mechanistic and preclinical studies in mice. We will examine how repetitive exposure to allergens and rhinovirus contributes to the development of steroid resistance. We will use genetically modified mice to validate the importance of steroid resistant pathways. We will perform preclinical trials with pathway inhibitors in a humanized mouse model of steroid resistant asthma. Under specific aim 3 we will establish the relevance of TSLP and TSLPR signaling molecules for steroid resistance by studying bronchoalveolar lavage ILCs and T cells from steroid resistant and steroid sensitive asthmatic patients. We will evaluate pathway inhibitors for reversal of steroid resistance of airway lymphoid cells. We have all the necessary expertise, resources and collaborators to accomplish this project. The proposal is important because it addresses an unresolved clinical problem that affects not only asthma but also many chronic inflammatory, autoimmune and neoplastic diseases where steroid resistance is a therapeutic challenge. A successful completion of this project will help develop novel therapeutic modalities targeting steroid resistance, in general.

文摘: